ACTRN12623001249640已完成Unknown
Immunogenicity of a third COVID-19 vaccine dose in people with multiple sclerosis receiving B cell-depleting therapy
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 入组人数
- 53
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Ability to understand requirements of the study, provide written informed consent and attend follow-up
- •-Age 18+ years
- •-Diagnosis of relapsing-remitting MS (RRMS), primary progressive MS (PPMS) or secondary progressive MS (SPMS)
- •-Receiving ocrelizumab or natalizumab as primary treatment with the last dose received within 24 months of vaccine administration
- •-Have elected to receive a third COVID-19 vaccine dose with a Therapeutic Goods Administration (TGA) approved mRNA-platform vaccine
排除标准
- •-Unable to provide written informed consent
- •-Acutely ill at the time of screening
- •-Is pregnant
- •-Known or suspected allergy or history of anaphylaxis to the vaccine or its excipients
- •-Has significant, uncontrolled disease or comorbidity (endocrine, cardiovascular, gastrointestinal, hepatic, renal, respiratory)
- •-Immunodeficiency (primary or secondary to infection e.g. HIV or cancer)
- •-Receiving systemic immunosuppressive agents including steroids - other than those required as per standard ocrelizumab or natalizumab treatment protocol
研究者
相似试验
进行中（未招募）
不适用
Immunogenicity of the 3rd COVID-19 vaccine dose in Thai healthcare workers at Bamrasnaradura Infectious Diseases InstituteHealthcare workers who received two doses of SinovacCOVID-19 VaccineSARS-CoV-2AntibodyHealthcare WorkersAstraZenecaPfizerTCTR20211005001ational Research Council of Thailand (NRCT)170
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine in Thai population.After the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months.COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, SinopharmTCTR20210731004Chulabhorn Royal Academy5,520
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine via intradermal compare with intramuscular administration (Randomized controlled trial)The immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers.COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, SinopharmTCTR20210731003Chulabhorn Royal Academy960
招募中
不适用
Pattern of antibody response after 3rd dose of COVID-19 vaccine booster among healthy volunteers.Healthy volunteerCOVID-19 Vaccinesadministration and dosageimmunologyTCTR20210831002akornping Hospital180
Unknown
3 期
Safety and immunogenicity of the third COVID-19 vaccines booster dose in children (12-18 years) with completed 2 doses as recommended by the ministry of public healthHealth adolescentsCOVID-19, booster, vaccineTCTR20221215006Chulalongkorn University320